Literature DB >> 2812231

Nerve growth factor in Alzheimer's disease: to treat or not to treat?

W C Mobley1.   

Abstract

Several hypotheses can be proposed to link neurotrophic factors with neurodegenerative diseases. Not surprisingly, different hypotheses suggest completely different approaches to therapy; some would suggest use of neurotrophic factors, while others would propose that the actions of these factors be blocked. It has been suggested that NGF be used to prevent the loss of basal forebrain cholinergic neurons in Alzheimer's disease (AD). At this time it is not possible to conclude whether or not NGF is implicated in the causation or progression of this disorder. Nevertheless, experimental studies in animals have given a strong rationale for its use. Given the lack of an effective treatment for this disorder, the careful approach to NGF trials outlined by an ad hoc committee of the National Institute on Aging should be pursued.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2812231     DOI: 10.1016/0197-4580(89)90135-8

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  3 in total

1.  A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis.

Authors:  H M Schätzl; L Laszlo; D M Holtzman; J Tatzelt; S J DeArmond; R I Weiner; W C Mobley; S B Prusiner
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Modulation of the PC12 cell response to nerve growth factor by antisense oligonucleotide to amyloid precursor protein.

Authors:  R E Majocha; S Agrawal; J Y Tang; E W Humke; C A Marotta
Journal:  Cell Mol Neurobiol       Date:  1994-10       Impact factor: 5.046

3.  TrkA expression in the CNS: evidence for the existence of several novel NGF-responsive CNS neurons.

Authors:  D M Holtzman; J Kilbridge; Y Li; E T Cunningham; N J Lenn; D O Clary; L F Reichardt; W C Mobley
Journal:  J Neurosci       Date:  1995-02       Impact factor: 6.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.